	US 11,987,602 B2
	Malonate transporters
Erin Marie Scott, Encinitas, CA (US); and Jacob Michael Vogan, San Diego, CA (US)
Assigned to CB Therapeutics, Inc., Carlsbad, CA (US)
Filed by CB Therapeutics, Inc., Carlsbad, CA (US)
Filed on Jun. 16, 2021, as Appl. No. 17/349,640.
Application 17/349,640 is a division of application No. 16/558,973, filed on Sep. 3, 2019, granted, now 11,041,002.
Prior Publication US 2021/0388035 A1, Dec. 16, 2021
Int. Cl. C12N 15/80 (2006.01); C07K 14/21 (2006.01); C12P 7/22 (2006.01); C12P 7/42 (2006.01); C12P 17/06 (2006.01)

CPC C07K 14/21 (2013.01) [C12N 15/80 (2013.01); C12P 7/22 (2013.01); C12P 7/42 (2013.01); C12P 17/06 (2013.01); C12Y 121/03007 (2015.07); C12Y 121/03008 (2015.07)]

13 Claims

1. A genetically modified microbial cell comprising at least one polypeptide that is non-naturally occurring in the cell and that allows for production of a terpene in the genetically modified microbial cell, and at least one malonate transporter gene that is non-naturally occurring in the cell, wherein the non-naturally occurring polypeptide comprises at least one enzyme selected from the group consisting of aromatic prenyltransferase (CBGAS), tetrahydrocannabiolicacid (THCA) synthase, cannabidiolic acid (CBDA) synthase, cannabichromenic acid (CBCA) synthase, aromatic prenyltransferase, malonyl CoA synthase, PKS olivetolic acid synthase and PKS olivetol synthase.